Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other cheapest stocks ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Bird flu has had a nationwide effect causing harm to the poultry and domestic animals but it also has been posing a risk to human health. While the health risk is low, people have been cautioned.

Influenza Vaccines Market is estimated to valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting CAGR of 7.1% from 2024-2031 BURLINGAME, CA, UNITED STATES, January ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator. Around the same time, a senior in Louisiana was diagnosed with the first ...

GSK plc (NYSE:GSK) is a leader in immunology, respiratory treatments, and vaccines for diseases such as influenza and shingles. GSK plc (NYSE:GSK) is focusing on building on its existing portfolio ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Prior to his time at Pfizer, Dormitzer also spent many years at Novartis, eventually rising to the position of head of research for the flu vaccine division. "GSK has an industry-leading pipeline ...

GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows ...